EGRX - Eagle Pharmaceuticals Inc


Moderate Growth and StableStock Price Very High


based on last 5 year data.
Income Statement is WEAK
Revenue Growth is -3.76%
Operating Income Growth is -74.43%
Net Income Growth is 13.96%
Earnings Per Share (EPS) Growth is 11.11%
Net Margin is 3.14%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 3.55
Debt Ratio is 0.28
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.14
Cash Flow is MODERATE
Cash from Operations Growth is 50.35%
Capital Expenditure is High
Net Increase in Cash is Positive
Long Term Score Trend is NEUTRAL
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Eagle Pharmaceuticals Inc (EGRX) -
Eagle Pharmaceuticals Inc. is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients' lives. Eagle's commercialized products include RYANODEX®, BENDEKA®, BELRAPZO®, and its oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states.
Exchange - NASDAQ
Industry - Pharmaceutical Preparation Manufacturing
Sector - Manufacturing
CEO - Scott Tarriff
Employees - 106

Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.